Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy.

PubWeight™: 1.71‹?› | Rank: Top 3%

🔗 View Article (PMID 21326294)

Published in J Invest Dermatol on February 17, 2011

Authors

Jasper G van den Boorn1, Daisy I Picavet, Paul F van Swieten, Henk A van Veen, Debby Konijnenberg, Peter A van Veelen, Toni van Capel, Esther C de Jong, Eric A Reits, Jan W Drijfhout, Jan D Bos, Cornelis J M Melief, Rosalie M Luiten

Author Affiliations

1: Department of Dermatology and The Netherlands Institute for Pigment Disorders, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Articles citing this

Vitiligo-inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8. J Invest Dermatol (2012) 2.02

ExoCarta as a resource for exosomal research. J Extracell Vesicles (2012) 1.69

A central role for inducible heat-shock protein 70 in autoimmune vitiligo. Exp Dermatol (2013) 1.50

Melanoma miRNA trafficking controls tumour primary niche formation. Nat Cell Biol (2016) 1.49

Autophagy in the regulation of pathogen replication and adaptive immunity. Trends Immunol (2012) 1.21

New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget (2011) 1.15

Antigen Processing for MHC Class II Presentation via Autophagy. Front Immunol (2012) 0.99

Innate immune mechanisms in vitiligo: danger from within. Curr Opin Immunol (2013) 0.97

Autophagy-associated immune responses and cancer immunotherapy. Oncotarget (2016) 0.88

Understanding mechanisms of autoimmunity through translational research in vitiligo. Curr Opin Immunol (2016) 0.86

Cellular stress and innate inflammation in organ-specific autoimmunity: lessons learned from vitiligo. Immunol Rev (2016) 0.80

Autoimmune vitiligo does not require the ongoing priming of naive CD8 T cells for disease progression or associated protection against melanoma. J Immunol (2014) 0.80

Preferential secretion of inducible HSP70 by vitiligo melanocytes under stress. Pigment Cell Melanoma Res (2014) 0.79

Vitiligo and alopecia areata: apples and oranges? Exp Dermatol (2013) 0.79

Understanding autoimmunity of vitiligo and alopecia areata. Curr Opin Pediatr (2016) 0.76

Melanoma-Targeted Chemothermotherapy and In Situ Peptide Immunotherapy through HSP Production by Using Melanogenesis Substrate, NPrCAP, and Magnetite Nanoparticles. J Skin Cancer (2013) 0.76

Enhanced bleaching treatment: opportunities for immune-assisted melanocyte suicide in vitiligo. Exp Dermatol (2014) 0.75

Chemical-Induced Vitiligo. Dermatol Clin (2017) 0.75

Immune and molecular correlates in melanoma treated with immune checkpoint blockade. Cancer (2017) 0.75

AC-1001 H3 CDR peptide induces apoptosis and signs of autophagy in vitro and exhibits antimetastatic activity in a syngeneic melanoma model. FEBS Open Bio (2016) 0.75

Whole Transcriptome Analysis (RNA Sequencing) of Peripheral Blood Mononuclear Cells of Vitiligo Patients. Dermatopathology (Basel) (2014) 0.75

Advances in Vitiligo: An Update on Medical and Surgical Treatments. J Clin Aesthet Dermatol (2017) 0.75

Breaking immunological tolerance to melanocyte differentiation antigens by hypopigmenting agents: a new means for melanoma immunotherapy? J Invest Dermatol (2011) 0.75

Targeting melanocyte and melanoma stem cells by 8-hydroxy-2-dipropylaminotetralin. Arch Biochem Biophys (2014) 0.75

Vitiligo Pathogenesis and Emerging Treatments. Dermatol Clin (2017) 0.75

Natural Killer Cell Memory: Progress and Implications. Front Immunol (2017) 0.75

Articles by these authors

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med (2009) 5.79

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med (2006) 4.84

Dendritic cell immunotherapy: mapping the way. Nat Med (2004) 4.28

CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest (2008) 3.11

Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. Proc Natl Acad Sci U S A (2005) 2.70

CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis. Arthritis Rheum (2003) 2.68

In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol (2006) 2.44

Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis Rheum (2005) 2.30

Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med (2003) 2.12

Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A (2011) 2.07

Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res (2008) 2.06

Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res (2009) 2.04

MHC II in dendritic cells is targeted to lysosomes or T cell-induced exosomes via distinct multivesicular body pathways. Traffic (2009) 1.98

High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res (2007) 1.96

Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc (2004) 1.95

Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol (2002) 1.93

Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res (2004) 1.90

How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol (2009) 1.87

The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol (2002) 1.84

Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet (2012) 1.81

Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol (2010) 1.77

Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One (2010) 1.73

Alpha-gliadin genes from the A, B, and D genomes of wheat contain different sets of celiac disease epitopes. BMC Genomics (2006) 1.70

Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A (2010) 1.67

Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J Immunol (2002) 1.66

Allo-HLA-reactive T cells inducing graft-versus-host disease are single peptide specific. Blood (2011) 1.66

Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res (2008) 1.66

Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann Rheum Dis (2006) 1.62

Altered penetration of polyethylene glycols into uninvolved skin of atopic dermatitis patients. J Invest Dermatol (2006) 1.62

Telomerase levels control the lifespan of human T lymphocytes. Blood (2003) 1.59

Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm. Cancer Res (2010) 1.59

Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis (2010) 1.59

Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol (2009) 1.56

Loss of TLR2, TLR4, and TLR5 on Langerhans cells abolishes bacterial recognition. J Immunol (2007) 1.55

CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol (2007) 1.54

Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci U S A (2007) 1.53

In vivo vitiligo induction and therapy model: double-blind, randomized clinical trial. Pigment Cell Melanoma Res (2011) 1.50

Differential kinetics of antigen-specific CD4+ and CD8+ T cell responses in the regression of retrovirus-induced sarcomas. J Immunol (2002) 1.46

Structural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes. Nat Immunol (2012) 1.46

Formation of fibrosis after nonablative and ablative fractional laser therapy. Dermatol Surg (2011) 1.41

The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease. Blood (2002) 1.41

Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res (2003) 1.40

Proteosomal degradation of BCR/ABL protein can generate an HLA-A*0301-restricted peptide, but high-avidity T cells recognizing this leukemia-specific antigen were not demonstrated. Haematologica (2004) 1.40

UVB 311 nm tolerance of vitiligo skin increases with skin photo type. Acta Derm Venereol (2005) 1.40

Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res (2011) 1.39

Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res (2005) 1.38

CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci U S A (2002) 1.34

Autoimmune etiology of generalized vitiligo. Curr Dir Autoimmun (2008) 1.31

Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin Cancer Res (2005) 1.30

Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. J Immunol (2004) 1.29

Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells. J Exp Med (2007) 1.28

Identification of citrullinated vimentin peptides as T cell epitopes in HLA-DR4-positive patients with rheumatoid arthritis. Arthritis Rheum (2010) 1.28

Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Eur J Immunol (2010) 1.27

Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res (2009) 1.27

MiR-17/20/93/106 promote hematopoietic cell expansion by targeting sequestosome 1-regulated pathways in mice. Blood (2011) 1.26

Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int J Cancer (2009) 1.26

Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes. PLoS One (2011) 1.26

Chemistry in living cells: detection of active proteasomes by a two-step labeling strategy. Angew Chem Int Ed Engl (2003) 1.25

Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes. Nat Immunol (2010) 1.24

Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells. J Biol Chem (2007) 1.23

Therapeutic cancer vaccines. J Clin Invest (2015) 1.23

New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer. J Transl Med (2012) 1.23

NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol (2008) 1.23

Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum (2002) 1.22

Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics (2002) 1.22

Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res (2002) 1.22

Efficient -2 frameshifting by mammalian ribosomes to synthesize an additional arterivirus protein. Proc Natl Acad Sci U S A (2012) 1.22

Methylation of arginine residues interferes with citrullination by peptidylarginine deiminases in vitro. J Mol Biol (2007) 1.21

Unique acquisition of cytotoxic T-lymphocyte escape mutants in infant human immunodeficiency virus type 1 infection. J Virol (2005) 1.20

LL-37 directs macrophage differentiation toward macrophages with a proinflammatory signature. J Immunol (2010) 1.20

Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J Immunol (2006) 1.19

Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects. Clin Cancer Res (2013) 1.18

Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat Med (2006) 1.17

Recognition of citrullinated and carbamylated proteins by human antibodies: specificity, cross-reactivity and the 'AMC-Senshu' method. Ann Rheum Dis (2012) 1.16

Ins and outs of dendritic cells. Int Arch Allergy Immunol (2006) 1.16

Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors. PLoS One (2011) 1.16

Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur J Immunol (2008) 1.16

Posttranslational modification of HLA-DQ binding islet autoantigens in type 1 diabetes. Diabetes (2013) 1.16

Development of novel LL-37 derived antimicrobial peptides with LPS and LTA neutralizing and antimicrobial activities for therapeutic application. Peptides (2005) 1.16

Human papillomavirus (HPV) upregulates the cellular deubiquitinase UCHL1 to suppress the keratinocyte's innate immune response. PLoS Pathog (2013) 1.15

Circulating preproinsulin signal peptide-specific CD8 T cells restricted by the susceptibility molecule HLA-A24 are expanded at onset of type 1 diabetes and kill β-cells. Diabetes (2012) 1.15

Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-I, bFGF and PDGF-AB compared to controls. Eur J Cell Biol (2002) 1.14